parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in oligodendrocytes (661 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	42 Parkinson's papers of 5,219	0.51
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 4872

receipt 4880: MOG in dopamine neurons, braak

power: full sample +0.18 (p 0.482, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.20 (p 0.434, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.045, n 18). not the mix.
skeptic: leave-one-out range +0.07 to +0.28, sign flips 0; without severely affected donors +0.18 (p 0.482, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MOG in dopamine neurons.

case closed: nothing better to follow up.

receipt 4879: MOG in oligodendrocytes, braak

power: full sample +0.12 (p 0.627, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.840, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.14 (p 0.579, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.26, sign flips 0; without severely affected donors +0.12 (p 0.627, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MOG in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts